OKYO Pharma
Tracked across 2 events · 15 articles · First seen Jan 30, 2026 · Last active Feb 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
OKYO Pharma's lead candidate, urcosimod, had an abstract accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting. This recognition highlights the potential of urcosimod for neuropathic corneal pain and supports the company's ongoing development efforts.
Jan 30, 2026 · 7 articles
Business
OKYO Pharma transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, replacing B. Riley Financial===B. Riley Securities Inc. This move provides OKYO Pharma with enhanced financial flexibility to raise capital opportunistically for its clinical development and corporate objectives.
Feb 11, 2026 · 8 articles
Robert Dempsey
Chief Executive Officer
↔
OKYO Pharma
Robert Dempsey is the Chief Executive Officer of OKYO Pharma.
Kiran Shah
Chief Financial Officer
↔
OKYO Pharma
Kiran Shah is the Chief Financial Officer of OKYO Pharma.
B. Riley Financial===B. Riley Securities
former client
↔
OKYO Pharma
OKYO Pharma was a client of B. Riley Financial===B. Riley Securities for its ATM
NEWSDESK
Track OKYO Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard